abhd11 Antibody

What is ABHD11 and why is it of interest to immunology researchers?

ABHD11 is a mitochondrial serine hydrolase that plays a critical role in T cell biology and function. Research interest in ABHD11 has increased significantly due to its association with clinical remission in rheumatoid arthritis (RA) when its expression is reduced in CD4+ T cells . ABHD11 maintains functional lipoylation of the DLST subunit of α-KGDH, which catalyzes the conversion of α-ketoglutarate (α-KG) to succinyl-CoA within the tricarboxylic acid (TCA) cycle . This metabolic function makes ABHD11 a critical node in T cell metabolism and activation, especially considering that ABHD11 expression is upregulated upon T cell receptor (TCR)-mediated activation . Understanding this protein's function provides new avenues for therapeutic intervention in autoimmune diseases where T cell hyperactivation contributes to pathology.

What applications are most common for ABHD11 antibodies in research settings?

ABHD11 antibodies are employed in multiple research applications with varying degrees of frequency based on experimental needs:

The choice of application depends on the specific research question, with Western blotting being particularly valuable for validating ABHD11 expression levels after genetic manipulation or inhibitor treatment . When working with human samples, researchers should be aware that commercially available ABHD11 antibodies predominantly target human ABHD11, though ortholog-reactive antibodies are also available for animal model studies .

How should researchers validate ABHD11 antibody specificity?

Validating antibody specificity is crucial for obtaining reliable research results. For ABHD11 antibodies, a multi-step validation approach is recommended:

• Positive and negative controls: Use cell lines or tissues with known ABHD11 expression levels. T cells before and after TCR activation provide an excellent control system as ABHD11 expression is upregulated upon activation .

• Knockdown/knockout validation: Compare antibody signal in wildtype versus ABHD11 knockdown or knockout samples. This is the gold standard for specificity confirmation.

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight of 34.7 kDa .

• Cross-reactivity testing: If studying ABHD11 in animal models, test for cross-reactivity with the species-specific ortholog.

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to block specific binding sites before application.

This comprehensive validation ensures that observed signals genuinely represent ABHD11 rather than non-specific binding or cross-reactivity with other abhydrolase domain-containing proteins.

How can researchers effectively use ABHD11 antibodies to study its role in T cell function?

To effectively study ABHD11's role in T cell function using antibodies, researchers should consider a multi-faceted approach:

• Expression profiling: Use ABHD11 antibodies for Western blot and flow cytometry to track expression changes during T cell activation. As demonstrated in recent studies, ABHD11 is expressed at low levels in unstimulated T cells but becomes notably upregulated upon TCR-mediated activation .

• Co-localization studies: Combine ABHD11 antibodies with mitochondrial markers in confocal microscopy to confirm its mitochondrial localization and potential co-localization with α-KGDH complex components.

• Functional correlation: Correlate ABHD11 expression levels (detected by immunoblotting) with cytokine production and metabolic parameters to establish functional relationships. This approach has revealed that ABHD11 inhibition significantly impairs cytokine production, including reductions in IL-17 and IFNγ in synovial fluid mononuclear cells from RA patients .

• Ex vivo patient analysis: Apply ABHD11 antibodies to compare expression in healthy versus autoimmune patient-derived T cells. Studies have successfully used this approach with CD4+ T cells from rheumatoid arthritis and type 1 diabetes patients .

• Kinetic studies: Track ABHD11 expression throughout the course of T cell activation to determine temporal dynamics of expression and any correlation with specific functional phases.

This methodological framework allows researchers to comprehensively assess ABHD11's role in T cell biology using antibody-based detection techniques.

What considerations should be made when designing immunoprecipitation experiments with ABHD11 antibodies?

When designing immunoprecipitation (IP) experiments with ABHD11 antibodies, researchers should consider several critical factors:

• Antibody selection: Choose antibodies specifically validated for IP applications. Not all ABHD11 antibodies perform equally in IP experiments.

• Mitochondrial protein extraction: Since ABHD11 is a mitochondrial protein, optimize mitochondrial isolation protocols to enrich for ABHD11 before IP. Standard whole-cell lysates may yield lower ABHD11 concentrations.

• Crosslinking considerations: If studying protein-protein interactions, mild crosslinking may preserve transient interactions between ABHD11 and other proteins of the α-KGDH complex or metabolic enzymes.

• Buffer composition: Use buffers that maintain mitochondrial protein interactions while solubilizing membranes. CHAPS or digitonin-based buffers often work better than stronger detergents like SDS for maintaining physiological interactions.

• Controls for specificity: Include:

  • IgG control from the same species as the ABHD11 antibody

  • IP from ABHD11-knockdown cells

  • Competitive blocking with immunizing peptide

• Co-IP targets: Consider probing for known ABHD11 interactors like components of the α-KGDH complex, particularly the DLST subunit, which requires ABHD11-mediated lipoylation for function .

Following these considerations will increase the likelihood of successful IP experiments that yield physiologically relevant results about ABHD11's molecular interactions.

How can ABHD11 antibodies be used to evaluate the efficacy of ABHD11 inhibitors?

ABHD11 antibodies serve as essential tools for evaluating ABHD11 inhibitor efficacy through multiple methodological approaches:

• Target engagement assays: Antibodies can be used in cellular thermal shift assays (CETSA) to determine whether inhibitors like ML-226 directly bind to ABHD11, causing thermal stabilization.

• Activity-based protein profiling: Use ABHD11 antibodies in conjunction with activity-based probes to determine the degree of active site occupancy by competitive inhibitors.

• Downstream functional validation: After inhibitor treatment (e.g., with ML-226 or WWL222), use ABHD11 antibodies to:

  • Confirm ABHD11 protein levels remain unchanged (ruling out expression effects)

  • Assess changes in post-translational modifications

  • Evaluate altered protein complex formation

• Correlation with phenotypic outcomes: Combine antibody-based ABHD11 detection with functional readouts such as cytokine production. Research has shown that ABHD11 inhibition impairs proinflammatory cytokine production with marked reductions in IFNγ, IL-2, IL-17, and TNFα in antigen-specific T cells .

• Monitoring compensatory responses: Use antibodies to track potential compensatory upregulation of ABHD11 or related proteins following chronic inhibitor treatment.

This multi-parameter approach using ABHD11 antibodies allows for comprehensive assessment of inhibitor efficacy at both the molecular target level and downstream functional consequences.

How can researchers use ABHD11 antibodies to investigate its role in metabolic reprogramming of T cells?

Investigating ABHD11's role in T cell metabolic reprogramming requires sophisticated application of antibody-based techniques:

• Metabolic flux analysis integration: Combine ABHD11 immunofluorescence with metabolic flux assays to correlate ABHD11 expression with metabolic phenotypes at the single-cell level. Research has shown that ABHD11 inhibition leads to impaired α-KGDH activity, resulting in reduced cellular succinate and a corresponding increase in the α-KG to succinate ratio .

• Mass spectrometry complementation: Use ABHD11 immunoprecipitation followed by mass spectrometry to identify:

  • Co-precipitating metabolic enzymes

  • Post-translational modifications affecting enzymatic function

  • Changes in protein interactions under different metabolic conditions

• Metabolite-protein interaction mapping: Employ proximity ligation assays with ABHD11 antibodies to visualize spatial relationships between ABHD11 and metabolic intermediates or enzymes during T cell activation.

• Dynamic analysis of mitochondrial networks: Combine ABHD11 antibody staining with mitochondrial morphology markers to assess how ABHD11 inhibition affects mitochondrial dynamics during metabolic reprogramming.

• In situ enzymatic activity correlation: Use ABHD11 antibodies in conjunction with DLST activity assays to correlate ABHD11 expression with α-KGDH function in single cells or tissue sections.

This integrative approach allows researchers to precisely map ABHD11's contribution to the metabolic changes that occur during T cell activation and differentiation, with particular relevance to autoimmune disease contexts.

What experimental considerations are important when using ABHD11 antibodies in tissue sections from autoimmune disease models?

When applying ABHD11 antibodies to tissue sections from autoimmune disease models, researchers should consider several advanced methodological approaches:

• Tissue-specific optimization: Adjust fixation protocols to preserve both ABHD11 epitopes and tissue architecture. Overfixation can mask epitopes while underfixation may compromise tissue morphology.

• Multi-parametric analysis: Combine ABHD11 staining with:

  • T cell subset markers (CD4, CD8, memory markers)

  • Activation markers (CD25, CD69)

  • Tissue-specific disease markers

  • Metabolic state indicators

• Spatial distribution analysis: Employ digital pathology tools to quantify:

  • ABHD11 expression gradients within tissue microenvironments

  • Correlation with inflammatory foci

  • Relationship to tissue damage markers

• Controls for specificity in tissues:

  • Include tissues from ABHD11 knockout models

  • Use competitive blocking with immunizing peptide

  • Include isotype controls specific to tissue type

• Temporal dynamics: When studying diseases like type 1 diabetes or rheumatoid arthritis, analyze tissues at different disease stages to track ABHD11 expression changes over time. Research has demonstrated that ABHD11 inhibition can delay the onset of diabetes in murine models of accelerated T1D .

• Correlation with in vivo treatment efficacy: In models treated with ABHD11 inhibitors like WWL222, correlate tissue ABHD11 expression with disease parameters. Studies have shown that daily administration of WWL222 delayed the onset of diabetes, underpinned by T cell-specific reduction in effector function .

These considerations ensure that ABHD11 antibody staining in tissues yields physiologically relevant data that can be correlated with disease progression and therapeutic outcomes.

How can ABHD11 antibodies be utilized to explore the mechanistic connection between ABHD11 and autoimmune disease pathogenesis?

Exploring the mechanistic connection between ABHD11 and autoimmune disease pathogenesis requires sophisticated application of antibody-based techniques:

• Patient-derived sample analysis: Use ABHD11 antibodies to:

  • Compare expression levels in T cells from patients versus healthy controls

  • Correlate ABHD11 expression with disease activity scores

  • Track expression changes during treatment response

• Functional correlation with patient outcomes: Research has demonstrated that reduced expression of ABHD11 within CD4+ T cells is associated with clinical remission in rheumatoid arthritis , suggesting a critical mechanistic link.

• Integrated single-cell analysis: Combine ABHD11 antibody detection with:

  • Single-cell transcriptomics

  • Metabolomic profiling

  • Functional assays (cytokine production, proliferation)
    to identify cell subsets where ABHD11 expression correlates with pathogenic function

• Pathway analysis validation: Use ABHD11 antibodies to confirm protein-level changes in pathways identified through transcriptomic or proteomic screening. Research has shown that ABHD11 inhibition impairs T cell effector function through metabolic rewiring, specifically through compromised TCA cycle function .

• In vivo therapeutic target validation: In models treated with ABHD11 inhibitors, use antibodies to confirm:

  • Target engagement in relevant tissues

  • Changes in downstream effector molecules

  • Correlation with disease amelioration

• Comparative analysis across autoimmune conditions: Apply ABHD11 immunostaining across multiple autoimmune disease models to identify common versus disease-specific mechanisms. Studies have already shown similar effects of ABHD11 inhibition in both rheumatoid arthritis and type 1 diabetes models .

This comprehensive approach enables researchers to establish causal relationships between ABHD11 function and autoimmune disease pathogenesis, supporting its emerging role as a therapeutic target.

What are common issues when working with ABHD11 antibodies and how can they be resolved?

Researchers working with ABHD11 antibodies may encounter several technical challenges that require methodological refinement:

• Low signal intensity in Western blots:

  • Solution: Optimize protein extraction protocols specifically for mitochondrial proteins. ABHD11 is localized to mitochondria, so standard whole-cell extraction may yield insufficient concentrations .

  • Methodology: Use mitochondrial isolation kits or digitonin-based fractionation to enrich for mitochondrial proteins before immunoblotting.

• High background in immunofluorescence:

  • Solution: Implement more stringent blocking and washing protocols.

  • Methodology: Consider using specialized blocking agents like mouse-on-mouse blocking reagents if using mouse monoclonal antibodies on mouse tissues.

• Inconsistent results across antibody lots:

  • Solution: Validate each new antibody lot against a standard sample.

  • Methodology: Maintain a reference lysate from cells with known ABHD11 expression levels to qualify new antibody lots.

• Cross-reactivity with other ABHD family members:

  • Solution: Confirm specificity using knockout/knockdown controls.

  • Methodology: Use CRISPR-Cas9 generated ABHD11-knockout cells as negative controls to confirm antibody specificity.

• Poor reproducibility in tissue immunostaining:

  • Solution: Standardize tissue processing and antigen retrieval protocols.

  • Methodology: Compare multiple antigen retrieval methods (heat-induced versus enzymatic) to determine optimal conditions for ABHD11 epitope exposure.

• Difficulty detecting endogenous ABHD11 in unstimulated T cells:

  • Solution: Implement signal amplification methods.

  • Methodology: Consider tyramide signal amplification or more sensitive detection systems, as ABHD11 is expressed at low levels in unstimulated T cells but becomes upregulated upon activation .

These troubleshooting approaches ensure more reliable and reproducible results when working with ABHD11 antibodies across various experimental platforms.

How can researchers optimize immunofluorescence protocols for co-localization studies with ABHD11 and mitochondrial markers?

Optimizing immunofluorescence protocols for ABHD11 co-localization with mitochondrial markers requires careful attention to several methodological details:

• Fixation optimization:

  • Test multiple fixation protocols (4% PFA, methanol, or combination fixation)

  • Determine optimal fixation time to preserve both ABHD11 epitopes and mitochondrial morphology

  • Consider light fixation (2% PFA for 10 minutes) followed by permeabilization for best results

• Sequential antibody application:

  • Apply primary antibodies sequentially rather than simultaneously

  • Start with the lower abundance target (typically ABHD11)

  • Block between applications to prevent cross-reactivity

• Confocal microscopy parameters:

  • Use appropriate pinhole settings (0.5-1 Airy units) to optimize optical sectioning

  • Acquire z-stacks with optimal step size (typically 0.3-0.5 μm)

  • Implement deconvolution algorithms to enhance signal-to-noise ratio

• Quantitative co-localization analysis:

  • Calculate Pearson's correlation coefficient and Mander's overlap coefficient

  • Implement object-based co-localization for more precise quantification

  • Use computational approaches to correct for chromatic aberration

• Controls for co-localization specificity:

  • Include single-stained samples to establish spectral bleed-through

  • Perform antibody competition assays to confirm specificity

  • Include samples with known altered mitochondrial morphology

• Super-resolution approaches:

  • Consider STED, STORM, or PALM microscopy for sub-mitochondrial localization

  • Implement pixel-reassignment techniques (Airyscan) for enhanced resolution with standard confocal systems

These methodological refinements enable precise characterization of ABHD11's subcellular localization and its spatial relationship with other mitochondrial proteins, providing insight into its functional role in mitochondrial metabolism.

What considerations should be made when designing experiments to study ABHD11 in primary human T cells from autoimmune disease patients?

Designing experiments to study ABHD11 in primary human T cells from autoimmune disease patients requires careful consideration of several methodological and biological factors:

• Sample collection and processing standardization:

  • Standardize blood collection tubes and processing times

  • Implement consistent T cell isolation protocols (magnetic or flow sorting)

  • Process all samples within the same timeframe to minimize ex vivo activation artifacts

• Patient stratification and clinical correlation:

  • Categorize patients based on disease activity, treatment status, and duration

  • Collect comprehensive clinical metadata for correlation analysis

  • Consider longitudinal sampling where possible to track ABHD11 expression over disease course

• Experimental controls:

  • Include age and sex-matched healthy controls

  • Consider disease controls (patients with other inflammatory conditions)

  • Include technical controls (cell lines with known ABHD11 expression)

• Functional validation approaches:

  • Combine ABHD11 antibody detection with functional assays

  • Correlate ABHD11 levels with cytokine production profile

  • Assess response to ABHD11 inhibitors ex vivo (as demonstrated with ML-226 in RA and T1D patient samples)

• Integrated analysis workflows:

  • Combine ABHD11 protein data with transcriptomic and metabolomic analysis

  • Implement computational methods to identify correlations between ABHD11 and disease parameters

  • Use machine learning approaches to identify patient subsets based on ABHD11-related signatures

• Ethical and practical considerations:

  • Ensure appropriate informed consent for mechanistic studies

  • Plan experiments to maximize data from limited patient samples

  • Consider sample storage protocols to enable future analysis as new techniques emerge

These methodological considerations enhance the rigor and reproducibility of studies examining ABHD11's role in human autoimmune disease, potentially leading to new therapeutic strategies targeting this protein.

How might ABHD11 antibodies be utilized in developing new therapeutic approaches for autoimmune diseases?

ABHD11 antibodies can play pivotal roles in developing novel therapeutic approaches for autoimmune diseases through several innovative research strategies:

• Target validation in diverse autoimmune contexts:

  • Use ABHD11 antibodies to evaluate expression across multiple autoimmune conditions beyond RA and T1D

  • Correlate expression levels with disease severity and treatment response

  • Identify patient subsets most likely to benefit from ABHD11-targeted therapies

• Therapeutic antibody development:

  • Develop antibodies targeting extracellular regions of ABHD11 (if present)

  • Engineer cell-penetrating antibodies to target intracellular ABHD11

  • Create antibody-drug conjugates to deliver ABHD11 inhibitors specifically to T cells

• Combination therapy optimization:

  • Use ABHD11 antibodies to monitor expression changes during standard-of-care treatments

  • Identify synergistic drug combinations that modulate both ABHD11 expression and function

  • Develop treatment algorithms based on ABHD11 expression patterns

• Biomarker development:

  • Establish ABHD11 expression as a potential biomarker for disease activity or treatment response

  • Develop standardized ABHD11 detection assays for clinical use

  • Validate ABHD11 as a predictor of response to metabolically targeted therapies

• Precision medicine applications:

  • Stratify patients based on ABHD11 expression profiles for clinical trials

  • Create companion diagnostics for ABHD11-targeted therapies

  • Develop personalized treatment regimens based on ABHD11 status

Research has already demonstrated that ABHD11 inhibition can delay the onset of diabetes in murine models and suppress cytokine production in T cells from autoimmune disease patients , providing strong rationale for further therapeutic development targeting this pathway.

What novel experimental approaches might enhance our understanding of ABHD11's role in T cell metabolism?

Advanced experimental approaches can significantly enhance our understanding of ABHD11's role in T cell metabolism:

• CRISPR-based functional genomics:

  • Combine CRISPR knockout of ABHD11 with antibody validation

  • Create knock-in reporter systems to track ABHD11 expression in real-time

  • Implement CRISPR screens to identify synthetic lethal interactions with ABHD11

• Integrated metabolic flux analysis:

  • Combine antibody-based ABHD11 quantification with stable isotope tracing

  • Track carbon flux through the TCA cycle in ABHD11-inhibited cells

  • Correlate ABHD11 levels with specific metabolic branch points

• Single-cell multi-omics approaches:

  • Implement CITE-seq to simultaneously assess ABHD11 protein and transcriptome

  • Develop spatial metabolomics approaches to map ABHD11 expression to metabolic microenvironments

  • Correlate ABHD11 with post-translational modifications at single-cell resolution

• Advanced imaging technologies:

  • Apply lattice light-sheet microscopy to track ABHD11 dynamics during T cell activation

  • Implement correlative light and electron microscopy to precisely locate ABHD11 within mitochondrial substructures

  • Use intravital imaging to visualize ABHD11 expression in tissue contexts

• Protein-metabolite interaction mapping:

  • Develop methods to capture direct interactions between ABHD11 and metabolic intermediates

  • Map the lipoylation landscape dependent on ABHD11 activity

  • Identify metabolite-sensitive regulatory domains within ABHD11

Recent research has established that ABHD11 maintains functional lipoylation of the DLST subunit of α-KGDH, which affects the conversion of α-KG to succinyl-CoA within the TCA cycle . These advanced approaches would further elucidate the mechanistic details and regulatory networks surrounding ABHD11's metabolic functions.

How can researchers integrate ABHD11 antibody-based detection with systems biology approaches to understand its broader impact on cellular networks?

Integrating ABHD11 antibody-based detection with systems biology approaches enables comprehensive understanding of its broader impact on cellular networks:

• Multi-scale protein interaction networks:

  • Use ABHD11 antibodies for proximity labeling (BioID, APEX) to map the complete ABHD11 interactome

  • Implement cross-linking mass spectrometry to capture transient interactions

  • Construct dynamic interaction networks that change during T cell activation states

• Integrated multi-omics data analysis:

  • Correlate ABHD11 protein levels with:

    • Transcriptomic changes

    • Global metabolomic profiles

    • Lipidomic alterations

    • Epigenetic modifications

  • Build predictive models of T cell function based on ABHD11 status

• Network perturbation analysis:

  • Use ABHD11 inhibitors or genetic manipulation combined with antibody detection to:

    • Map network responses to ABHD11 perturbation

    • Identify compensatory mechanisms

    • Discover critical nodes in ABHD11-dependent pathways

• Computational modeling approaches:

  • Develop ordinary differential equation models of ABHD11's role in TCA cycle dynamics

  • Create agent-based models of T cell activation incorporating ABHD11 regulation

  • Implement machine learning to predict drug responses based on ABHD11 network states

• Translational network medicine:

  • Map ABHD11-centered networks across:

    • Multiple immune cell types

    • Different autoimmune diseases

    • Treatment response patterns

  • Identify common network motifs that could serve as therapeutic targets

Research has shown that ABHD11 inhibition rewires mitochondrial metabolism, affecting the TCA cycle and subsequently activating LXR signaling . These systems biology approaches would provide a comprehensive view of how ABHD11 integrates into broader cellular networks, potentially revealing novel therapeutic opportunities beyond direct ABHD11 targeting.